VTGN250117P2000
- 0.20
- 0.000.00%
VistaGen Therapeutics Newsroom
Stifel Maintains VistaGen Therapeutics(VTGN.US) With Buy Rating, Maintains Target Price $12
VistaGen Therapeutics' Promising Clinical Progress and Strong Financial Position Justify Buy Rating
Maxim Group Maintains VistaGen Therapeutics(VTGN.US) With Buy Rating, Maintains Target Price $12
Maxim Group Maintains VistaGen Therapeutics(VTGN.US) With Buy Rating, Maintains Target Price $12
Buy Rating Affirmed on VistaGen Therapeutics Amid Strong Financials and Promising Clinical Trials
Analysts Offer Insights on Healthcare Companies: VistaGen Therapeutics (VTGN) and Acrivon Therapeutics, Inc. (ACRV)
Jefferies Upgrades Vistagen Therapeutics to Buy, Raises Price Target to $15
Vistagen Therapeutics Analyst Ratings
Hearing Vistagen Therapeutics Upgraded From A Hold To A Buy At Jefferies; Price Target $15
Vistagen Therapeutics Analyst Ratings
VistaGen Therapeutics' Robust Financial Position and Promising Pipeline Underpin Buy Rating: A Comprehensive Analysis
Analysts Offer Insights on Healthcare Companies: VistaGen Therapeutics (VTGN) and Rhythm Pharmaceuticals (RYTM)
Maxim Cuts Price Target on VistaGen Therapeutics to $12 From $30, Maintains Buy Rating
Maxim Group Reaffirms Their Buy Rating on VistaGen Therapeutics (VTGN)
Analysts Offer Insights on Healthcare Companies: CymaBay Therapeutics (CBAY) and VistaGen Therapeutics (VTGN)
Maxim Group Maintains Buy on Vistagen Therapeutics, Maintains $30 Price Target
Vistagen Therapeutics Analyst Ratings
Maxim Group Remains a Buy on VistaGen Therapeutics (VTGN)
Maxim Group Upgrades Vistagen Therapeutics to Buy, Announces $30 Price Target
Vistagen Therapeutics Analyst Ratings